Number 5: Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and ...

Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable ...